Blood Feud: The Man Who Blew the Whistle on One of the Deadliest Prescription Drugs Ever

Kathleen Sharp

sept 2011 · Tantor Media Inc · Narración de Coleen Marlo

Información sobre este audiolibro

Blood-boosting Procrit is Johnson & Johnson's biotech superstar. Behind its various brand names, it ranks as Medicare's most reimbursed drug. But Procrit performs frighteningly well, and can stimulate so many blood cells that thousands of patients die in unexplained and painful ways. And that's not all: Cancer patients, who often receive injections, are never warned that the drug stimulates tumor growth, too, prompting one leading hematologist to dub it "Miracle-Gro for cancer." While patients have no clue about the risks behind this poorly tested drug, Johnson & Johnson sales rep Mark Duxbury knows precisely what is happening-the pharma behemoth is blatantly marketing overdoses of the drug. Duxbury tries to warn his superiors and is forced to testify in a secret court about illegal schemes. But his honesty costs him his career. Humiliated and ignored for years, Duxbury is ultimately betrayed in a shockingly cruel way. The psychological trauma drives him to attempt suicide, yet he fights on for several more years until the heartbreaking end. A Civil Action's Jan Schlichtmann has taken on the case, and is back in federal district court in Massachusetts. And all the while, Johnson & Johnson has continued to push sales of Procrit. Blood Feud is award-winning journalist Kathleen Sharp's nail-biting expose of the Procrit case. Packed with corporate espionage, plot twists, and larger-than-life characters, it's as gripping as it is terrifyingly true.

Acerca del autor

Kathleen Sharp is an award-winning journalist whose work has appeared in vanity Fair and the New York Times Magazine and the author of Mr. & Mrs. Hollywood and In Good Faith.

AudioFile Earphones Award winner Coleen Marlo has earned numerous Publishers Weekly Listen-Up Awards and won an Audie Award for her narration of Snakewoman of Little Egypt by Robert Hellenga.